Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Vascular pain caused by contrast media (CM) cannot be quantified by subjective patient reports or manifest pain reactions in experimental animals. Therefore, conditioned taste aversion (CTA), a psychopharmacological method, was used in double-blind femoral arteriography in rats to compare a new nonionic monomeric CM, ioxilan, with iohexol, iopamidol (all at 350 mgI/mL) and 22% sorbitol. A chronically implanted femoral artery catheter was used to inject 0.2 mL/kg body weight. By measuring the intake of water laced with the flavor that thirsty rats had learned to associate with the injection, the degree of aversion, assumed proportional to pain, was determined. Ioxilan (690 mOsm) produced the least pain, followed by iopamidol (810 mOsm), iohexol (844 mOsm) and sorbitol (1410 mOsm). Since all test substances are highly and similarly hydrophilic and nonionic, the intensity of vascular pain must depend on solution osmolality, rather than on chemotoxicity or ionicity. Compounds of the lowest osmolality, ig, ioxilan, elicit the least vascular pain.
 ...
PMID:Current contrast media and ioxilan. Comparative evaluation of vascular pain by aversion conditioning. 319 69

After a brief historical review of non-symptomatic pain, the authors describe the typical form of vascular pain in the face, a definite clinical entity. As is in the case in other specialties, they now prefer the term vascular pain to that of sympathalgia, still often used in our own discipline. Vascular pain occurs by paroxysmal attacks centred upon the orbit, accompanied by typical vasomotors signs. The treatment proposed is based upon the use alone or in association of dihydroergotamine, methysergide and beta-blockers.
 ...
PMID:[Facial vascular pain and sympathalgia. Therapeutic trial]. 658 57

The general pharmacological study of iodixanol, a non-ionic isotonic contrast medium, was conducted. 1) Iodixanol administered intravenously over a dose range of 320 to 3,200 mgI/kg had little or no effect on the general behavior, spontaneous locomotor activity, hexobarbital sleeping time, pain response, electroshock- or pentylenetetrazol-induced convulsion (mouse), EEG or body temperature (rabbit), gastrointestinal propulsion (mouse) or skeletal muscle contraction (rabbit). Iodixanol had no specific interaction with acetylcholine, histamine, serotonin, nicotin, BaCl2 (ileum), methacholine (trachea), isoprenaline (atrium) or oxytocin (pregnant uterus), nor had any effect on spontaneous contractility (atrium and uterus), or transmural electrostimulation-induced contractility (vas deferens) at concentrations of < or = 3.2 x 10(-3) gI/ml in vitro. Iodixanol had no effect on the cardiovascular system of dog, except that it increased femoral blood flow and respiratory rate at doses of > or = 1,000 mgI/kg. Iodixanol at 3,200 mgI/kg i.v. reduced urine output with a decrease in Na+ and Cl- excretion, whereas at 320 mgI/kg i.v., it slightly increased urine output (rat). 2) Injections of iodixanol into the cerebroventricular (0.96, 9.6 mgI/mouse and 3.2, 32 mgI/rat), left ventricular (1,920, 6,400 mgI/dog) or coronary artery (640, 1,920 mgI/dog) had no conspicuous effect on the central nervous system or the cardiovascular system, respectively. There was no marked difference among iodixanol, iohexol and iopamidol in this respect. Vascular pain during injection into the femoral artery (300-320 mgI/guinea pig) appeared to be less intense with iodixanol, compared with the other contrast media iohexol and iopamidol. These results suggest that intravenous injection of iodixanol is relatively free from pharmacological activity, and effects of iodixanol on the central nervous system (intracerebroventricular injection) and cardiovascular system (intra-left ventricular and -coronary injections) are comparable to those of iohexol and iopamidol. Furthermore, intra-femoral injection of iodixanol has less of a tendency to produce vascular pain than those of iohexol and iopamidol.
 ...
PMID:[General pharmacological study of iodixanol, a new non-ionic isotonic contrast medium]. 749 Jul 85

Studies investigating the cerebral representations of pain using functional imaging techniques failed to elucidate the affective aspects of pain. This investigation used functional magnetic resonance imaging to measure pain-related changes in cerebral activity during painful stimulation with a strong affective component. Vascular pain was induced via balloon dilatation of a dorsal foot vein of healthy volunteers. The subjects rated their perceived pain uninterruptedly during imaging, allowing cerebral activity to be correlated with both stimulus function (boxcar) and, more importantly, subjective ratings reflecting individual pain experience. The findings indicated signal increases in subcortical-limbic regions, particularly in the amygdala. This region is suggested to be involved in the affective dimension of pain.
 ...
PMID:Subjective ratings of pain correlate with subcortical-limbic blood flow: an fMRI study. 1128 97